Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Rises By 26.0%

GeoVax Labs Inc. (NASDAQ:GOVX) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 265,418 shares, an increase of 26.0% from the February 26th total of 210,698 shares. Approximately 14.6% of the shares of the company are sold short. Based on an average trading volume of 69,667 shares, the days-to-cover ratio is currently 3.8 days.

Analyst Ratings Changes

Several brokerages have weighed in on GOVX. Wall Street Zen downgraded shares of GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Finally, D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, February 19th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, GeoVax Labs has a consensus rating of “Hold” and an average price target of $187.50.

GeoVax Labs Stock Up 1.1%

NASDAQ GOVX traded up $0.02 on Wednesday, reaching $1.40. The company had a trading volume of 5,002 shares, compared to its average volume of 137,194. The stock has a market capitalization of $2.54 million, a PE ratio of -0.04 and a beta of 3.81. GeoVax Labs has a 12 month low of $1.26 and a 12 month high of $34.75. The firm’s 50 day moving average price is $2.00 and its 200 day moving average price is $7.65.

Hedge Funds Weigh In On GeoVax Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sabby Management LLC bought a new stake in GeoVax Labs in the 3rd quarter worth approximately $313,000. Renaissance Technologies LLC bought a new position in shares of GeoVax Labs during the 4th quarter valued at approximately $104,000. Jane Street Group LLC bought a new position in GeoVax Labs during the fourth quarter valued at $99,000. Armistice Capital LLC purchased a new position in shares of GeoVax Labs in the 3rd quarter worth $253,000. Finally, HRT Financial LP bought a new stake in shares of GeoVax Labs in the 4th quarter worth about $31,000. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.